Department of Radiation Oncology, Shizuoka City Shizuoka Hospital, 10-93, Ohtemachi, Shizuoka, Aoi-ku, 420-8630, Japan.
Department of Oral and Maxillofacial Surgery, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
BMC Cancer. 2020 Dec 10;20(1):1216. doi: 10.1186/s12885-020-07707-2.
The prognosis of advanced oral cancer remains dismal. While multimodal therapy is beneficial, maintaining the quality of life of long-term survivors is important. Therefore, risk-adapted treatment regimens need to be designed. We herein investigated whether pathological responses in oral cancer patients treated with preoperative chemoradiotherapy predict locoregional recurrence.
We retrospectively reviewed the data of 51 oral cancer patients who received preoperative radiotherapy and concurrent pepleomycin, followed by curative surgery at our institution between January 2009 and June 2018. Each patient received preoperative external beam irradiation to the primary tumor and lymphatics (2 Gy per day for approximately 3 weeks) concurrent with pepleomycin (2.5 mg/day). Surgery was performed approximately 3-4 weeks after the completion of preoperative chemoradiotherapy. Pathological responses were defined based on the grading system of Oboshi and Shimosato.
Eight, 22, 16, and 5 patients had Oboshi and Shimosato grades 2a, 2b, 3, and 4, respectively. Favorable pathological responses (grades 3 and 4) were observed in 41.2% of patients (21 out of 51 patients). The pathological response and number of pathological lymph node metastases were identified as significant prognostic factors for locoregional control in the univariate analysis. Three-year locoregional control rates were 100 and 56.6% in patients with favorable and unfavorable pathological responses, respectively.
The present study demonstrated that pathological tumor responses to preoperative chemoradiotherapy are a useful predictive factor for locoregional control.
晚期口腔癌的预后仍然不佳。虽然多模态治疗有益,但维持长期生存者的生活质量很重要。因此,需要设计风险适应的治疗方案。我们在此研究了接受术前放化疗的口腔癌患者的病理反应是否可以预测局部区域复发。
我们回顾性分析了 2009 年 1 月至 2018 年 6 月期间在我院接受术前放疗和同时顺铂治疗、然后行根治性手术的 51 例口腔癌患者的数据。每位患者接受原发肿瘤和淋巴结的术前外照射(每天 2Gy,约 3 周),同时给予顺铂(2.5mg/天)。术前放化疗完成后约 3-4 周进行手术。病理反应根据 Oboshi 和 Shimosato 的分级系统定义。
8、22、16 和 5 例患者的 Oboshi 和 Shimosato 分级分别为 2a、2b、3 和 4。41.2%的患者(51 例患者中的 21 例)观察到良好的病理反应(分级 3 和 4)。单因素分析显示,病理反应和病理淋巴结转移数是局部区域控制的显著预后因素。在有良好和不良病理反应的患者中,3 年局部区域控制率分别为 100%和 56.6%。
本研究表明,术前放化疗的肿瘤病理反应是局部区域控制的一个有用的预测因素。